SynthesisCritical care (London, England)2014
High-volume hemofiltration for septic acute kidney injury: a systematic review and meta-analysis.
Synthesis in Critical care (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 5 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Effects on mortality of different blood purification techniques in sepsis patients: an umbrella review of systematic reviews and meta-analyses.Renal failure · 2026Pooled it
- Effect of High-Volume Hemofiltration in Critically Ill Patients: A Systematic Review and Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2019Pooled it
- The efficacy of renal replacement therapy strategies for septic-acute kidney injury: A PRISMA-compliant network meta-analysis.Medicine · 2019Pooled it
- High-volume haemofiltration for sepsis in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Intensity of continuous renal replacement therapy for acute kidney injury.The Cochrane database of systematic reviews · 2016Pooled it
- CVVHD results in longer filter life than pre-filter CVVH: Results of a quasi-randomized clinical trial.PloS one · 2023Trial
- Changes of Serum Procalcitonin (PCT), C-Reactive Protein (CRP), Interleukin-17 (IL-17), Interleukin-6 (IL-6), High Mobility Group Protein-B1 (HMGB1) and D-Dimer in Patients with Severe Acute Pancreatitis Treated with Continuous Renal Replacement Therapy (CRRT) and Its Clinical Significance.Medical science monitor : international medical journal of experimental and clinical research · 2018Trial
- High-volume hemofiltration in adult burn patients with septic shock and acute kidney injury: a multicenter randomized controlled trial.Critical care (London, England) · 2017Trial
- Mortality Reduction in Septic Shock by Plasma Adsorption (ROMPA): a protocol for a randomised clinical trial.BMJ open · 2016Trial
- Very high volume hemofiltration with the Cascade system in septic shock patients.Intensive care medicine · 2015Trial
- Chimeric IL-6/4R-LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Continuous renal replacement therapy for septic shock: practicalities for a pediatric intensivist.European journal of pediatrics · 2026Review
- Renal replacement therapy in intensive care unit: a narrative review.Annals of intensive care · 2026Review
- Effluent-Dose Response of Continuous Haemofiltration Integrated into Veno-Venous ECMO for Septic Shock: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Continuous Hemofiltration During Extracorporeal Membrane Oxygenation in Adult Septic Shock: A Comparative Cohort Analysis.Biomedicines · 2025Article
- Plasma exchange in septic shock: are we ready for prime time? CON.Intensive care medicine · 2024Article
- Has the CONVINCE trial convinced the nephrology and dialysis community?Annals of translational medicine · 2024Article
- Polymyxin B Hemoperfusion in Sepsis: A Possible Silver Lining to the Dark Clouds?Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Extracorporeal organ support for critically ill patients: Overcoming the past, achieving the maximum at present, and redefining the future.World journal of critical care medicine · 2024Article
- Adjunctive immunotherapeutic agents in patients with sepsis and septic shock: a multidisciplinary consensus of 23.Journal of anesthesia, analgesia and critical care · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHigh-volume hemofiltration (HVHF) is an attractive therapy for the treatment of septic acute kidney injury (AKI). Small experimental and uncontrolled studies have suggested hemodynamic and survival benefits at higher doses of HVHF than those used for the high-intensity arms of the RENAL and ATN studies. Our aim was to evaluate the effects of high-volume hemofiltration (HVHF) compared with standard-volume hemofiltration (SVHF) for septic AKI.
methodsA systematic review and meta-analysis of publications between 1966 and 2013 was performed. The review was limited to randomized-controlled trials that compared HVHF (effluent rate greater than 50 ml/kg per hour) versus SVHF in the treatment of sepsis and septic shock. The primary outcome assessed was 28-day mortality. Other outcomes assessed were recovery of kidney function, lengths of ICU and hospital stays, vasopressor dose reduction, and adverse events.
resultsFour trials, including 470 total participants, were included. Pooled analysis for 28-day mortality did not show any meaningful difference between HVHF compared with SVHF (OR, 0.76; 95% CI, 0.45 to 1.29). No included studies reported statistically significant differences between groups for any of the secondary outcomes. Adverse events, including hypophosphatemia and hypokalemia, were more commonly observed in HVHF-treated patients, although reporting was inconsistent across studies.
conclusionsInsufficient evidence exists of a therapeutic benefit for routine use of HVHF for septic AKI, other than on an experimental basis. Given the logistic challenges related to patient recruitment along with an incomplete understanding of the biologic mechanisms by which HVHF may modify outcomes, further trials should focus on alternative extracorporeal therapies as an adjuvant therapy for septic AKI rather than HVHF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.